Last reviewed · How we verify

NCT04609839: TeleRea'nCo

FOLLOW-UP OF PATIENTS WITH COVID-19.

Withdrawn Last updated 16 September 2025
What this trial tests

trial testing Follow-up of patients with COVID-19 in Patient Admitted to Intensive Care Unit for COVID-19. Withdrawn.

Timeline
15 September 2020
Primary endpoint
17 October 2023
17 October 2023

Quick facts

Lead sponsorUniversity Hospital, Strasbourg, France
StatusWithdrawn
Study typeOBSERVATIONAL
Start date15 September 2020
Primary completion17 October 2023
Estimated completion17 October 2023
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Strasbourg, France

Who can join

18 and older, any sex, with Patient Admitted to Intensive Care Unit for COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Some patients admitted to intensive care for a severe form of COVID-19 could have respiratory, cardiac, renal and neurological sequelae in the medium or long term. The results of this research will allow an improvement in the understanding and management of patients in the medium and long term.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Post-acute COVID-19 syndrome and kidney diseases: what do we know?
    Copur S, Berkkan M, Basile C, Tuttle K, et al · · 2022 · cited 39× · PMID 35294747 · DOI 10.1007/s40620-022-01296-y

Verify or expand the search:

Other University Hospital, Strasbourg, France trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04609839.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing